# CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System

> **NCT03013868** · — · UNKNOWN · sponsor: **MiCareo Taiwan Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Circulating Tumor Cells, CTC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03013868
- **Lead sponsor:** MiCareo Taiwan Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2020-12
- **Final completion:** 2021-02
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03013868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03013868, "CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03013868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*